This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Today's Small-Cap Winners & Losers

Innodata Isogen (INOD - Get Report) soared almost 60% after the Hackensack, N.J.-based Internet-technology company said it had signed about $9 million worth in service contracts, mostly with major publishers, bringing known 2007 revenue to about $40 million so far. Shares were up $1.21 to $3.23.

Insmed (INSM) shares were leaping after the Italian government requested that its Iplex drug be made available for treatment of Lou Gehrig's disease in Italy. Cephalon (CEPH), which holds the European patent rights to that use of Iplex, will distribute the drug through a government program, and Insmed will see unspecified payments from the Italian Health Authorities. Richmond, Va.-based Insmed was rising 18 cents, or 17.5%, to $1.21. Cephalon shares were dipping 66 cents to $69.56.

Genomic Health (GHDX - Get Report) surged on word that insurance giant UnitedHealth Group (UNH - Get Report) had agreed to cover the biotech's Oncotype DX test service, which predicts disease recurrence and chemotherapy effectiveness for breast cancer patients. California-based Genomic was up $3.52, or 17%, to $24.20. UnitedHealth shares were unchanged.

Cosi (COSI - Get Report) gained after the restaurant chain estimated that 2006 losses had narrowed by a dime a share from 2005 to 18 cents. Analysts are seeking a loss of 25 cents, according to Thomson Financial. Revenue totals for the quarter and year won't quite meet Street projections, but the Deerfield, Ill., company also forecast 2007 earnings between 8 cents and 12 cents a share, which would quash the downside consensus. Shares were adding 62 cents, or 11.8%, to $5.89.

Scientific-instruments maker LeCroy (LCRY) fell after it predicted $38 million revenue in the fiscal second quarter ended Dec. 31 -- $4 million less than last year and $4.5 million short of analysts' projections. On a GAAP basis it will probably lose $8 million, including costs related to its October acquisition of Catalyst Enterprises and stock-based compensation, reversing $2.2 million profits a year ago. Shares were down $1.28, or 11.2%, to $10.15.

Active Power (ACPW - Get Report) sank after the Austin-based power-products maker announced it will conduct an internal review of its historical stock option grants, which could delay the filing of its annual report should any "significant issues" arise. Shares were losing 20 cents, or 7.7%, to $2.40.

Adaptec (ADPT) dropped after preliminary fiscal third-quarter results were short of expectations. The Milipitas, Calf., storage company expects losses by both GAAP and non-GAAP measures, missing the penny-a-share earnings estimate and the company's own prior guidance. Sales, likely between $60 million and $61 million, will also miss the $72.6 million Wall Street projections. Shares were sliding 34 cents, or 7.6%, to $4.16.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs